Targacept to Report Third Quarter 2012 Financial Results on November 6, 2012

Before you go, we thought you'd like these...
Before you go close icon

Targacept to Report Third Quarter 2012 Financial Results on November 6, 2012

WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept Inc. (NAS: TRGT) , a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™ , today announced that it will report financial results for the third quarter of 2012 on Tuesday, November 6, 2012, after the U.S. financial markets close.

Management will discuss the third quarter financial results, provide an update on the company's product development programs and business activities, and discuss expectations for the future via conference call at 5:00 p.m. Eastern Time on Tuesday, November 6, 2012. The conference call may be accessed by dialing 800.706.7741 for domestic participants and 617.614.3471 for international callers (reference passcode 78046906). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Time on November 6, 2012 through November 20, 2012 by dialing 888.286.8010 for domestic callers and 617.801.6888 for international callers (reference passcode 85901627).


A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept's website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept's website for at least two weeks following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept's clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

TARGACEPT
Building Health, Restoring Independence®



Targacept, Inc.
Alan Musso, SVP, Finance and Administration and CFO
336-480-2186
alan.musso@targacept.com
or
Linnden Communications
Michelle Linn, 508-362-3087
linnmich@comcast.net

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:

The article Targacept to Report Third Quarter 2012 Financial Results on November 6, 2012 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners